Concepedia

Mary Giffear

MG

Statistics

Publications

7

Citations

1.2K

H-Index

7

Active since

2012

Affiliations

Inovio Pharmaceuticals (United States)(Current)

University of Pennsylvania

The Wistar Institute

Johns Hopkins Medicine

Johns Hopkins University

Mary Giffear is an author at Inovio Pharmaceuticals (United States) specializing in immunology, vaccinology, and immunization.

Publications per year

2012–2022

7

Publications

7

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 714 citations

, , +17

Immunotherapy Against HPV16/18 Generates Potent T <sub>H</sub> 1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow et al. · Science Translational Medicine · 2012 · 283 citations · Full text

, , +13

Tolerability of intramuscular and intradermal delivery by CELLECTRA<sup>®</sup>adaptive constant current electroporation device in healthy volunteers

Malissa Diehl, Jessica C. Lee, Stephen E. Daniels et al. · Human Vaccines & Immunotherapeutics · 2013 · 93 citations · Full text

, , +17

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes et al. · The Journal of Infectious Diseases · 2022 · 61 citations · Full text

, , +17

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

Mammen P. Mammen, Pablo Tebas, Joseph Agnes et al. · medRxiv · 2021 · 43 citations · Full text

, , +17

1–5 of 7